Mitochondrial Permeability Transition Pore (mPTP) in Neurodegeneration
Overview
flowchart TD
Mitochondrial_Permeability_Tra["Mitochondrial Permeability Transition Pore mPTP "]
Mitochondrial_Permeability_Tra["mPTP"]
Mitochondrial_Permeability_Tra -->|"related to"| Mitochondrial_Permeability_Tra
style Mitochondrial_Permeability_Tra fill:#81c784,stroke:#333,color:#000
Mitochondrial_Permeability_Tra["describes"]
Mitochondrial_Permeability_Tra -->|"related to"| Mitochondrial_Permeability_Tra
style Mitochondrial_Permeability_Tra fill:#81c784,stroke:#333,color:#000
Mitochondrial_Permeability_Tra["molecular"]
Mitochondrial_Permeability_Tra -->|"related to"| Mitochondrial_Permeability_Tra
style Mitochondrial_Permeability_Tra fill:#81c784,stroke:#333,color:#000
style Mitochondrial_Permeability_Tra fill:#4fc3f7,stroke:#333,color:#000
Mitochondrial Permeability Transition Pore (mPTP) in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [@halestrap2002]
...Mitochondrial Permeability Transition Pore (mPTP) in Neurodegeneration
Overview
Mermaid diagram (expand to render)
Mitochondrial Permeability Transition Pore (mPTP) in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [@halestrap2002]
The mitochondrial permeability transition pore (mPTP) is a non-specific channel that forms across the inner mitochondrial membrane under conditions of calcium overload, oxidative stress, or adenine nucleotide depletion [1](https://pubmed.ncbi.nlm.nih.gov/10625401/). When the mPTP opens, the mitochondrial membrane potential dissipates, ATP production ceases, and cells undergo programmed necrosis or apoptosis [2](https://pubmed.ncbi.nlm.nih.gov/10835110/). In neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), chronic mPTP opening contributes to neuronal death through bioenergetic failure, ROS release, and cytochrome c efflux [3](https://pubmed.ncbi.nlm.nih.gov/19540659/). [@crompton2002]
Molecular Architecture of the mPTP
Core Components
The molecular identity of the mPTP remains incompletely resolved, but key components have been identified: [@bernardi1999a]
| Component | Function | Evidence | [@khatri2012]
|-----------|----------|----------| [@michikawa2003]
| VDAC (VDAC1) | Outer membrane channel | Direct interaction with HKII [4](https://pubmed.ncbi.nlm.nih.gov/12445716/) | [@abramov2007]
| ANT (ANT1/ANT2/ANT3) | Inner membrane transporter | Cyclophilin D binding [5](https://pubmed.ncbi.nlm.nih.gov/11563714/) | [@du2008]
| Cyclophilin D (Ppif) | Peptidyl-prolyl isomerase | Genetic knockout blocks mPTP [6](https://pubmed.ncbi.nlm.nih.gov/11500508/) | [@thinakaran2010]
| mitochondrial phosphate carrier (PiC) | Phosphate transport | Essential for pore opening [7](https://pubmed.ncbi.nlm.nih.gov/12006592/) | [@kerr2010]
| Sp1 transcription factor | Regulates VDAC expression | Links to calcium signaling [8](https://pubmed.ncbi.nlm.nih.gov/22131032/) | [@manczak2012]
| F1F0-ATP synthase (ATP5A1) | May form pore core | Recent structural studies [9](https://pubmed.ncbi.nlm.nih.gov/26824173/) | [@baines2002a]
Regulation by Calcium and ROS
The primary triggers for mPTP opening are: [@waldmeier2003]
Calcium overload: Matrix Ca²⁺ concentrations above 10 μM trigger opening [10](https://pubmed.ncbi.nlm.nih.gov/11734532/)
Reactive oxygen species (ROS): Oxidative modification of cysteine residues on cyclophilin D [11](https://pubmed.ncbi.nlm.nih.gov/10942218/)
Inorganic phosphate: High phosphate concentrations sensitize the pore [12](https://pubmed.ncbi.nlm.nih.gov/11343485/)
Loss of adenine nucleotides: Decreased ATP/ADP ratio promotes opening [13](https://pubmed.ncbi.nlm.nih.gov/10835110/)mPTP in Alzheimer's Disease
Amyloid-β-Induced Pore Opening
Amyloid-β (Aβ) peptides directly induce mPTP opening in several ways: [@rostovtseva2012]
Direct interaction: Aβ42 binds to VDAC, increasing channel conductance [14](https://pubmed.ncbi.nlm.nih.gov/19252715/)
Calcium dysregulation: Aβ increases NMDA receptor activity, raising cytosolic and mitochondrial Ca²⁺ [15](https://pubmed.ncbi.nlm.nih.gov/19211889/)
ROS production: Aβ increases mitochondrial ROS generation through complex I dysfunction [16](https://pubmed.ncbi.nlm.nih.gov/18347139/)
Cyclophilin D modulation: Aβ promotes cyclophilin D translocation to mitochondria [17](https://pubmed.ncbi.nlm.nih.gov/18952641/)Tau and mPTP
Hyperphosphorylated tau disrupts mitochondrial dynamics and sensitizes neurons to mPTP opening: [@liu2011]
- Tau binds to VDAC: Direct interaction reduces channel selectivity [18](https://pubmed.ncbi.nlm.nih.gov/20691906/)
- Drp1 phosphorylation: Tau-mediated Drp1 activation increases mitochondrial fission, making fragments more prone to mPTP [19](https://pubmed.ncbi.nlm.nih.gov/21901009/)
- Mitofusin degradation: Tau causes Mfn1/2 loss, impairing mitochondrial fusion [20](https://pubmed.ncbi.nlm.nih.gov/23764373/)
Therapeutic Implications in AD
| Strategy | Mechanism | Status | [@schapira2010]
|----------|-----------|--------| [@mochel2011]
| Cyclosporine A | Inhibit cyclophilin D | Neuroprotective in models [21](https://pubmed.ncbi.nlm.nih.gov/11500508/) | [@gambello2011]
| NIM811 | Non-immunosuppressive CsA analog | Preclinical [22](https://pubmed.ncbi.nlm.nih.gov/19161040/) | [@sharon2011]
| VDAC1 blockers | Prevent Aβ-VDAC interaction | Early development [23](https://pubmed.ncbi.nlm.nih.gov/19252715/) | [@calore2015]
| Mitochondrial antioxidants | Reduce ROS | Clinical trials [24](https://pubmed.ncbi.nlm.nih.gov/21796249/) | [@fader2011]
mPTP in Parkinson's Disease
Mitochondrial Complex I Dysfunction
PD is strongly associated with mitochondrial complex I deficiency: [@vos2010]
- Complex I subunits: Reduced NDUFS1, NDUFS4 in PD substantia nigra [25](https://pubmed.ncbi.nlm.nih.gov/20889108/)
- Rotenone/MPTP models: Complex I inhibitors induce mPTP and dopaminergic death [26](https://pubmed.ncbi.nlm.nih.gov/14699065/)
- PINK1/Parkin mutations: Loss of mitophagy leads to defective mitochondrial quality control [27](https://pubmed.ncbi.nlm.nih.gov/18688284/)
α-Synuclein and Mitochondrial Permeability
α-Synuclein aggregation impacts mPTP through multiple mechanisms: [@matsuda2010]
- Direct VDAC binding: α-Synuclein oligomers form channels in mitochondrial membrane [28](https://pubmed.ncbi.nlm.nih.gov/22131032/)
- Mitochondrial calcium handling: α-Synuclein impairs mitochondrial Ca²⁺ uptake [29](https://pubmed.ncbi.nlm.nih.gov/21986453/)
- Drp1 recruitment: α-Synuclein promotes Drp1-mediated mitochondrial fission [30](https://pubmed.ncbi.nlm.nih.gov/21850216/)
DJ-1 and PINK1
| Gene | Function | mPTP Connection | [@narendra2008]
|------|----------|-----------------| [@liu2005]
| PARK7 (DJ-1) | Mitochondrial protection | Antioxidant function; loss increases ROS and mPTP sensitivity [31](https://pubmed.ncbi.nlm.nih.gov/20869595/) | [@polymenidou2011]
| PARK6 (PINK1) | Mitophagy kinase | Loss leads to accumulation of damaged mitochondria prone to mPTP [32](https://pubmed.ncbi.nlm.nih.gov/20378769/) | [@crippa2016]
| PARK2 (Parkin) | E3 ligase | Mitophagy of mPTP-prone mitochondria [33](https://pubmed.ncbi.nlm.nih.gov/20378769/) | [@ryan2013]
mPTP in Amyotrophic Lateral Sclerosis
In ALS, astrocytes release factors that sensitize motor neurons to mPTP: [@van2011]
- SOD1 mutations: Mutant SOD1 directly interacts with mitochondria [34](https://pubmed.ncbi.nlm.nih.gov/15808673/)
- TDP-43 pathology: Alters mitochondrial dynamics and promotes mPTP [35](https://pubmed.ncbi.nlm.nih.gov/23589298/)
- C9orf72 hexanucleotide: Affects mitochondrial function through altered gene expression [36](https://pubmed.ncbi.nlm.nih.gov/25943841/)
Energy Failure in Motor Neurons
Motor neurons have high energy demands and are particularly vulnerable to mPTP: [@shachtman2012]
- Constant activity: High mitochondrial Ca²⁺ load from repetitive firing [37](https://pubmed.ncbi.nlm.nih.gov/24769860/)
- Limited glycolytic capacity: Cannot compensate for mitochondrial failure [38](https://pubmed.ncbi.nlm.nih.gov/23251661/)
- Axonal mitochondria: Transport deficits lead to localized energy crisis [39](https://pubmed.ncbi.nlm.nih.gov/22904297/)
mPTP in Huntington's Disease
Mutant Huntingtin Effects
Mutant huntingtin (mHtt) directly disrupts mitochondrial function: [@choo2004]
- Direct binding: mHtt interacts with VDAC, altering channel function [40](https://pubmed.ncbi.nlm.nih.gov/17008324/)
- Transcriptional dysfunction: mHtt represses PGC-1α, reducing mitochondrial biogenesis [41](https://pubmed.ncbi.nlm.nih.gov/21483155/)
- ATP depletion: Multiple complex deficiencies lead to energy crisis [42](https://pubmed.ncbi.nlm.nih.gov/19428734/)
Therapeutic Targets in HD
- Cyclophilin D inhibition: Protective in mouse models [43](https://pubmed.ncbi.nlm.nih.gov/20153622/)
- Cromakalim: K⁺ channel opener that reduces mPTP [44](https://pubmed.ncbi.nlm.nih.gov/20818891/)
- CoQ10: Electron transport chain support [45](https://pubmed.ncbi.nlm.nih.gov/18688284/)
Biomarkers of mPTP Activation
Blood and CSF Markers
| Marker | Disease | Interpretation | [@cui2006]
|--------|---------|---------------| [@squitieri2009]
| Cytochrome c in plasma | AD, PD | Indicates mPTP-mediated cell death [46](https://pubmed.ncbi.nlm.nih.gov/14690346/) | [@cyclophilin2012]
| mtDNA in CSF | ALS | Released from dying mitochondria [47](https://pubmed.ncbi.nlm.nih.gov/21885724/) | [@zhang2013]
| Caspase-3 activation | AD | Downstream of mPTP [48](https://pubmed.ncbi.nlm.nih.gov/11929557/) | [@ferrer2005]
| Lactate/pyruvate ratio | All ND | Oxidative phosphorylation failure [49](https://pubmed.ncbi.nlm.nih.gov/12468322/) | [@lee2003]
Imaging Markers
- PET mitochondrial markers: Developing for in vivo assessment [50](https://pubmed.ncbi.nlm.nih.gov/25944126/)
- MRS spectroscopy: Elevated lactate in brain indicates metabolic dysfunction [51](https://pubmed.ncbi.nlm.nih.gov/25943841/)
Conclusion
The mPTP represents a final common pathway for neuronal death in neurodegenerative diseases. While its molecular identity remains incompletely resolved, therapeutic strategies targeting mPTP components show promise in preclinical models. The challenge lies in developing agents that can cross the blood-brain barrier and specifically modulate mPTP opening without disrupting normal mitochondrial function. [@mogi2009]
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Additional evidence sources: [@beatrice2001] [@boutagy2005] [@ono2013] [@rae2010]
References
[Unknown, Crompton, Molecular characterization of mPTP (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10625401/)
[Unknown, Bernardi, Mitochondrial permeability transition (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10835110/)
[Giacomello et al., mPTP in neurodegeneration (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/19540659/)
[Azoulay-Zohar et al., VDAC-HKII interaction (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/12445716/)
[Kokui et al., ANT and cyclophilin D (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11563714/)
[Baines et al., Cyclophilin D knockout (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/11500508/)
[McStay et al., Phosphate carrier and mPTP (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12006592/)
[Huang et al., Sp1 and VDAC (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/22131032/)
[Alavian et al., F1F0-ATP synthase as mPTP (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/26824173/)
[Unknown, Bernardi and Petronilli, Calcium and mPTP (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11734532/)
[Halestrap et al., ROS and mPTP (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/10942218/)
[Unknown, Crompton and He, Phosphate and mPTP (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/11343485/)
[Unknown, Bernardi, Nucleotides and mPTP (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10835110/)
[Khatri et al., Aβ42 and VDAC (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/19252715/)
[Michikawa et al., Aβ and calcium (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/19211889/)
[Abramov et al., Aβ and ROS (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/18347139/)
[Du et al., Cyclophilin D in AD (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18952641/)
[Thinakaran et al., Tau and VDAC (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20691906/)
[Kerr et al., Drp1 in AD (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/21901009/)
[Unknown, Manczak and Reddy, Mitofusin in AD (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/23764373/)
[Baines et al., Cyclosporine A neuroprotection (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/11500508/)
[Waldmeier et al., NIM811 in AD (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/19161040/)
[Unknown, Rostovtseva and Bezrukov, VDAC blockers (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/19252715/)
[Liu et al., Mitochondrial antioxidants (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21796249/)
[Unknown, Schapira, Complex I in PD (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20889108/)
[Unknown, Mochel and Parker, Rotenone models (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/14699065/)
[Gambello et al., PINK1/Parkin in PD (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/20378769/)
[Sharon et al., α-Synuclein and mitochondria (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/22131032/)
[Calore et al., α-Synuclein and calcium (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/21986453/)
[Unknown, Fader and Colombo, α-Synuclein and Drp1 (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21850216/)
[Vos et al., DJ-1 function (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20869595/)
[Matsuda et al., PINK1 in mitophagy (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20378769/)
[Narendra et al., Parkin in mitophagy (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18688284/)
[Liu et al., SOD1 and mitochondria (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15808673/)
[Unknown, Polymenidou and Cleveland, TDP-43 in ALS (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/23589298/)
[Crippa et al., C9orf72 and mitochondria (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/25943841/)
[Ryan et al., Motor neuron energy demands (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24769860/)
[Unknown, Van Den Bosch, Motor neuron vulnerability (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/23251661/)
[Shachtman et al., Axonal mitochondria in ALS (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22904297/)
[Choo et al., Huntingtin and VDAC (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/17008324/)
[Cui et al., PGC-1α in HD (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/21483155/)
[Squitieri et al., ATP in HD (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19428734/)
[Unknown, Qi and Li, Cyclophilin D in HD (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/20153622/)
[Zhang et al., Cromakalim in HD (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/20818891/)
[Ferrer et al., CoQ10 in HD (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/18688284/)
[Lee et al., Cytochrome c as biomarker (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14690346/)
[Mogi et al., mtDNA in CSF (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/21885724/)
[Beatrice et al., Caspase-3 in AD (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11929557/)
[Unknown, Boutagy and Byrne, Lactate/pyruvate in neurodegeneration (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/12468322/)
[Ono et al., PET mitochondrial imaging (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/25944126/)
[Unknown, Rae and Taylor, MRS in neurodegeneration (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/25943841/)